Becton Dickinson (BDX) Posts Strong AGILITY Trial Results, Is The Stock Still Below Fair Value?

Becton Dickinson (BDX) just put fresh clinical data in front of investors. Nine-month results from the AGILITY trial for its Revello Vascular Covered Stent showed the study hit its primary endpoint in iliac artery disease. Recent clinical progress comes on top of a busy October for Becton Dickinson, including a new U.S. government manufacturing partnership and a leadership change in its Surgery unit, while a separate product recall underscored ongoing execution risk across the...